Stocktoria
Propanc Biopharma, Inc. PPCB
Propanc Biopharma, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $223,721 | $248,102 | $247,919 | $256,052 | $230,956 | $179,987 | $260,335 | $1.8M | $971,769 | $1.4M |
| Operating income | -$57.3M | -$1.5M | -$1.8M | -$2.0M | -$1.8M | -$3.5M | -$2.6M | -$4.0M | -$5.7M | -$6.9M |
| Interest expense | — | — | $532,821 | $568,798 | $449,457 | $1.7M | $1.3M | $2.8M | $3.2M | $4.5M |
| Income tax | — | -$129,132 | -$129,841 | -$54,977 | -$113,415 | -$134,728 | -$115,437 | -$179,306 | -$305,673 | -$72,538 |
| Net income | -$58.9M | -$1.8M | -$2.7M | -$2.7M | -$2.0M | -$4.7M | -$5.8M | -$7.0M | -$7.9M | -$9.4M |
| EPS (diluted) | $-14.85 | $-1420.53 | $-1.80 | $-49.23 | — | — | — | — | — | — |
| Operating cash flow | -$405,168 | -$935,118 | -$1.1M | -$1.4M | -$1.1M | -$1.8M | -$2.1M | -$2.2M | -$2.1M | -$4.5M |
| Free cash flow | — | — | — | — | — | — | -$2.1M | — | — | -$4.5M |
| Cash & equivalents | — | — | — | $4,067 | $2,255 | $67,007 | — | — | — | — |
| Total assets | $19.6M | $72,365 | $60,328 | $81,651 | $13,101 | $98,518 | $101,652 | $71,387 | $95,069 | $379,142 |
| Total liabilities | $5.7M | $3.9M | $3.2M | $3.1M | $3.1M | $3.7M | $4.4M | — | — | — |
| Shareholders' equity | $13.9M | -$3.8M | -$3.1M | -$3.0M | -$3.1M | -$3.6M | -$4.3M | -$6.8M | -$5.4M | -$2.6M |
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.